1,841 results match your criteria Cardiovascular Diabetology[Journal]


Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.

Cardiovasc Diabetol 2020 Jul 9;19(1):110. Epub 2020 Jul 9.

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT).

Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofogliflozin treatment group (n = 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n = 171). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01079-4DOI Listing

Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study.

Cardiovasc Diabetol 2020 Jul 9;19(1):111. Epub 2020 Jul 9.

State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing, 100037, China.

Background: Merging studies have reported the association of lipoprotein(a) [Lp(a)] with poor outcomes of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). However, the prognostic importance of Lp(a) for recurrent cardiovascular events (CVEs) is currently undetermined in patients with T2DM and prior CVEs.

Methods: From April 2011 to March 2017, we consecutively recruited 2284 T2DM patients with prior CVEs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01083-8DOI Listing

Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China.

Cardiovasc Diabetol 2020 Jul 8;19(1):108. Epub 2020 Jul 8.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, 100029, China.

Background: The relationship between triglyceride-glucose index (TyG index) and the prevalence and prognosis of cardiovascular disease has been confirmed by former studies. However, it remains uncertain whether TyG index has a prognostic impact in patients with type 2 diabetes mellitus (T2DM) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI).

Methods: The study retrospectively enrolled 798 patients (mean age: 60. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01086-5DOI Listing

The association between glucose-related variables and plaque morphology in patients with ST-segment elevated myocardial infarction.

Cardiovasc Diabetol 2020 Jul 8;19(1):109. Epub 2020 Jul 8.

Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.

Background: Plaque rupture (PR) and plaque erosion (PE) are main causes of acute myocardial infarction with different demographic and histology characteristics and need different treatment strategy. PR and PE can be identified with optical coherence tomography (OCT) accurately, but convenient and effective noninvasive markers for them are rarely found. History of diabetes mellitus (DM) was reported to be a potential predictor of PR in ST-segment elevated myocardial infarction (STEMI) patients, but the predictive value of other glucose-related variables for it is still uncertain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01074-9DOI Listing

Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.

Authors:
Bo Liang Ning Gu

Cardiovasc Diabetol 2020 Jul 6;19(1):106. Epub 2020 Jul 6.

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.

There are many glucose-lowering agents used in patients with heart failure, showing mixed results, this study was conducted to determine the effect of liraglutide, a glucagon-like peptide-1 analogue, on the treatment of patients with heart failure. Patients from the FIGHT and LIVE trials were included, all overlapped data were summarized and described. No significant changes from baseline in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, hemoglobin A1c, heart rate, left ventricular end-systolic volume index, left ventricular end-diastolic volume index, and 6 min walk test were observed in FIGHT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01088-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339504PMC

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.

Cardiovasc Diabetol 2020 Jul 6;19(1):107. Epub 2020 Jul 6.

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns vej 7, 2100, Copenhagen Ø, Denmark.

Background: In randomised clinical trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduced cardiovascular events in patients with type 2 diabetes (T2D) at high cardiovascular risk, as compared to standard care. However, data comparing these agents in patients with T2D who are at moderate risk is sparse.

Methods: From Danish national registries, we included patients with T2D previously on metformin monotherapy, who started an additional glucose-lowering agent [GLP-1 RA, SGLT-2 inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitor, sulfonylurea (SU), or insulin] in the period 2010-2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01078-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339487PMC

Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.

Cardiovasc Diabetol 2020 Jul 6;19(1):105. Epub 2020 Jul 6.

Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Background: To assess the associations of various HbA1c measures, including a single baseline HbA1c value, overall mean, yearly updated means, standard deviation (HbA1c-SD), coefficient of variation (HbA1c-CV), and HbA1c variability score (HVS), with microvascular disease (MVD) risk in patients with type 2 diabetes.

Methods: Linked data between National Cheng Kung University Hospital and Taiwan's National Health Insurance Research Database were utilized to identify the study cohort. The primary outcome was the composite MVD events (retinopathy, nephropathy, or neuropathy) occurring during the study follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01082-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339461PMC

The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes.

Cardiovasc Diabetol 2020 Jul 6;19(1):104. Epub 2020 Jul 6.

State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing, 100037, China.

Background: The atherogenicity of remnant cholesterol (RC) has been underlined by recent guidelines, which was linked to coronary artery disease (CAD), especially for patients with diabetes mellitus (DM). This study aimed to examine the prognostic value of plasma RC in the patients with CAD under different glucose metabolism status.

Methods: Fasting plasma RC were directly calculated or measured in 4331 patients with CAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01076-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339517PMC

Prior bariatric surgery and perioperative cardiovascular outcomes following noncardiac surgery in patients with type 2 diabetes mellitus: hint from National Inpatient Sample Database.

Cardiovasc Diabetol 2020 Jul 6;19(1):103. Epub 2020 Jul 6.

Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhong Shan Er Lu, Guangzhou, 510080, China.

Background: Both diabetes and obesity are risk factors for perioperative major adverse events. This study aims to evaluate the association between prior bariatric surgery (prior-BS) and perioperative cardiovascular outcomes following noncardiac surgery in patients with type 2 diabetes mellitus (T2DM).

Methods: We used the National Inpatient Sample Database to identify T2DM patients undergoing major noncardiac surgery from 2006 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01084-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339406PMC

Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction.

Cardiovasc Diabetol 2020 Jul 4;19(1):101. Epub 2020 Jul 4.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.

Background: Left ventricular systolic dysfunction (LVSD) occurs frequently after acute ST-segment elevation myocardial infarction (STEMI). The predisposing factors and underlying mechanism of post-infarct LVSD are not fully understood. The present study mainly investigated the correlation between glycaemic gap, a novel index of stress-induced hyperglycaemia (SIH), and post-infarct LVSD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01075-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335441PMC

Glycemic variability: adverse clinical outcomes and how to improve it?

Cardiovasc Diabetol 2020 Jul 4;19(1):102. Epub 2020 Jul 4.

Department of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.

Glycemic variability (GV), defined as an integral component of glucose homoeostasis, is emerging as an important metric to consider when assessing glycemic control in clinical practice. Although it remains yet no consensus, accumulating evidence has suggested that GV, representing either short-term (with-day and between-day variability) or long-term GV, was associated with an increased risk of diabetic macrovascular and microvascular complications, hypoglycemia, mortality rates and other adverse clinical outcomes. In this review, we summarize the adverse clinical outcomes of GV and discuss the beneficial measures, including continuous glucose monitoring, drugs, dietary interventions and exercise training, to improve it, aiming at better addressing the challenging aspect of blood glucose management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01085-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335439PMC

Long-term outcomes of medical therapy versus successful recanalisation for coronary chronic total occlusions in patients with and without type 2 diabetes mellitus.

Cardiovasc Diabetol 2020 Jul 4;19(1):100. Epub 2020 Jul 4.

Department of Cardiology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, People's Republic of China.

Background: In this study, we compared the outcomes of medical therapy (MT) with successful percutaneous coronary intervention (PCI) in chronic total occlusions (CTO) patients with and without type 2 diabetes mellitus.

Methods: A total of 2015 patients with CTOs were stratified. Diabetic patients (n = 755, 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01087-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335447PMC

Cardiovascular and diabetes burden attributable to physical inactivity in Mexico.

Cardiovasc Diabetol 2020 Jun 29;19(1):99. Epub 2020 Jun 29.

Department of Epidemiology and Biostatistics, Center for Vulnerable Populations, University of California, San Francisco, CA, USA.

Background: Physical inactivity (PI) is associated with the development of non-communicable chronic diseases. The purposes of this study were to estimate the extent to which the 31% relative increase in PI among 35-64 years old Mexicans between 2006 and 2012 influenced diabetes (T2D) and cardiovascular disease (CVD) incidence and mortality, and to estimate the impact of the World Health Organization recommended 10% and 15% relative decrease in PI on CVD and T2D incidence and mortality by 2025 and 2030, respectively.

Methods: Estimates were derived using the Cardiovascular Disease Policy Model-Mexico, a computer simulation, Markov model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01050-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325101PMC

SGLT2i: beyond the glucose-lowering effect.

Cardiovasc Diabetol 2020 Jun 26;19(1):98. Epub 2020 Jun 26.

Department of Nephrology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei, 430071, China.

Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the heart and kidney, which can significantly reduce cardiovascular events, delay the progression of renal failure, greatly improve the quality of life of patients, and reduce medical expenses for families and society. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01071-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320582PMC

Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.

Cardiovasc Diabetol 2020 Jun 22;19(1):96. Epub 2020 Jun 22.

Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Background: The cardiovascular outcome trials (CVOTs) have shown that glucagon like peptide-1 receptor agonists (GLP1RAs) have varying degrees of cardiovascular (CV) safety in patients with type 2 diabetes mellitus (T2DM.) The lack of any head-to-head comparative trials among GLP1RAs urged the need for an indirect comparison of these agents. Therefore, this study was conducted to indirectly compare the CV safety and mortality effects among different GLP1RAs in patients with T2DM using network meta-analysis (NMA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01070-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310317PMC

Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort.

Cardiovasc Diabetol 2020 Jun 22;19(1):97. Epub 2020 Jun 22.

Division of Cardiology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 20, Eonju-ro 63-gil, Gangnam-gu, Seoul, 06229, South Korea.

Background: The influence of intensive glucose control in diabetic patients on the macrovascular outcomes is controversial. Thus, this study aimed to elucidate the effect of preprocedural hemoglobin A1c (HbA1c) on clinical outcomes after endovascular therapy for lower extremity artery disease (LEAD) in diabetic patients.

Methods: Diabetic patients were enrolled from the retrospective cohorts of a Korean multicenter endovascular therapy registry and were divided according to the HbA1c level during index admission into the optimal (< 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01072-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310391PMC

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.

Cardiovasc Diabetol 2020 Jun 22;19(1):95. Epub 2020 Jun 22.

College of Pharmacy, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea.

Background: Dapagliflozin is one of the novel glucose-lowering agents, which has recently been reported to reduce the risk of hospitalization for heart failure (hHF). The present study aimed to compare the differences between the risk of hHF after using dapagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i) as second-line drugs for the treatment of type 2 diabetes mellitus using the latest nationwide population data in Korea. Additionally, we aimed to examine the impact of clinical outcomes on direct medical costs in the two groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01060-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310428PMC

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.

Cardiovasc Diabetol 2020 Jun 20;19(1):94. Epub 2020 Jun 20.

Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.

Background: Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare. Thus, we aimed to assess the effect of pioglitazone on primary stroke prevention in Asian patients with type 2 DM without established CV diseases but with risk factors for CV diseases.

Methods: Between 2000 and 2012, we enrolled patients aged ≥ 18 years, who were newly diagnosed with type 2 diabetes and had at least one of the following CV risk factors: hypertension and hyperlipidemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01056-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306145PMC

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).

Cardiovasc Diabetol 2020 Jun 19;19(1):93. Epub 2020 Jun 19.

Zydus Discovery DMCC, Dubai, UAE.

Background: The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention. The PRESS XII study primarily aimed to evaluate the efficacy and safety of saroglitazar (2 mg and 4 mg) as compared to pioglitazone 30 mg on glycemic control in patients with type 2 diabetes mellitus.

Methods: In this randomized double-blind study, patients with T2DM [glycosylated hemoglobin (HbA1c) ≥ 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01073-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305598PMC

Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.

Cardiovasc Diabetol 2020 Jun 17;19(1):92. Epub 2020 Jun 17.

John Paul II Hospital, Kraków, Poland.

Background: Accumulation of advanced glycation end products (AGEs) leads to chronic glycation of proteins and tissue damage, particularly in patients with diabetes mellitus (DM). We aimed to evaluate whether increased accumulation of AGEs in patients with aortic stenosis (AS) and concomitant type 2 diabetes (DM) is associated with AS severity.

Methods: We prospectively enrolled 76 patients with severe AS (47. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01068-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301463PMC

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.

Cardiovasc Diabetol 2020 Jun 15;19(1):89. Epub 2020 Jun 15.

Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan.

Background: Fatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibly leading to a drug class effect and each drug effect. Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naïve and sulfonylurea-treated patients with type 2 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01061-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296623PMC

Exercise-induced albuminuria increases over time in individuals with impaired glucose metabolism.

Cardiovasc Diabetol 2020 Jun 15;19(1):90. Epub 2020 Jun 15.

Department of Internal Medicine "C", "D" and "E", Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 64239, Tel Aviv, Israel.

Background: Exercise induced albuminuria (EiA) is elevated in patients with metabolic dysfunction and diabetes, and may serve as an early biomarker for endothelial dysfunction and "kidney reserve". However, the change in EiA levels over time and its interaction with metabolic dysfunction and glucose metabolism has never been studied. Therefore, we sought to determine EiA levels over time in a cohort of individuals attending a routine annual health survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01058-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296954PMC

Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study.

Cardiovasc Diabetol 2020 Jun 15;19(1):88. Epub 2020 Jun 15.

Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.

Backgrounds: The role of right ventricular (RV) and atrial (RA) structure and function, in the increased heart failure risk in (pre)diabetes is incompletely understood. The purpose of this study is to investigate the associations between (pre)diabetes and RV and RA structure and function, and whether these are mediated by left ventricular (LV) alterations or pulmonary pressure.

Methods: Participants of the Maastricht Study; a population-based cohort study (426 normal glucose metabolism (NGM), 142 prediabetes, 224 diabetes), underwent two-dimensional and tissue Doppler echocardiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01055-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296751PMC

Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.

Cardiovasc Diabetol 2020 Jun 15;19(1):91. Epub 2020 Jun 15.

Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Background: A sodium-glucose co-transporter 2 (SGLT-2) inhibitor had favorable impact on the attenuation of hyperglycemia together with the severity of heart failure. However, the effects of acute dapagliflozin administration at the time of cardiac ischemia/reperfusion (I/R) injury are not established.

Methods: The effects of dapagliflozin on cardiac function were investigated by treating cardiac I/R injury at different time points. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01066-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296726PMC

Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy.

Cardiovasc Diabetol 2020 Jun 13;19(1):84. Epub 2020 Jun 13.

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Background: Left ventricular (LV) longitudinal dysfunction has been identified in type 2 diabetes mellitus (T2DM) patients with preserved LV ejection fraction (LVEF). However, the impact of T2DM on LV longitudinal function or the association of LV longitudinal function with outcome for dilated cardiomyopathy (DCM) remains unclear.

Methods: We retrospectively studied 206 patients with non-ischemic DCM, mean age of 59 ± 17 years and LVEF of 31 ± 8% (all < 45%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01063-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293795PMC

Type 2 diabetes mellitus increases the mortality risk after acute coronary syndrome treated with coronary artery bypass surgery.

Cardiovasc Diabetol 2020 Jun 13;19(1):86. Epub 2020 Jun 13.

Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, 52621, Tel Hashomer, Israel.

Background: Type 2 diabetes mellitus (DM) is a risk factor for cardiovascular diseases and is common among patients undergoing coronary artery bypass grafting (CABG) surgery. The main objective of our study was to investigate the impact of DM type 2, and its treatment subgroups, on short- and long-term mortality in patients with acute coronary syndrome (ACS) who undergo CABG.

Methods: The study included 1307 patients enrolled from the biennial Acute Coronary Syndrome Israeli Survey between 2000 and 2016, who were hospitalized for ACS and underwent CABG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01069-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293781PMC

Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.

Cardiovasc Diabetol 2020 Jun 13;19(1):87. Epub 2020 Jun 13.

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari, Italy.

Background: Cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors (SGLT2i CVOTs) found the agents to be associated with clinical benefits in terms of cardiovascular and renal outcomes. We performed a meta-analysis to assess and compare the overall prevalence of eligibility for the enrollment criteria of CANVAS, DECLARE-TIMI 58, EMPA-REG OUTCOME, and VERTIS-CV among unselected patients with type 2 diabetes.

Methods: This meta-analysis was registered in PROSPERO (CRD42020172032). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01067-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293778PMC

Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study.

Cardiovasc Diabetol 2020 Jun 13;19(1):81. Epub 2020 Jun 13.

Huh's Diabetes Center and the 21st Century Diabetes and Vascular Research Institute, Seoul, Korea.

Background: There is increasing concern regarding cardiovascular risk in individuals with non-alcoholic fatty liver disease. This study was conducted to evaluate whether hepatic steatosis with or without fibrosis is associated with the progression of carotid atherosclerosis in patients with type 2 diabetes.

Methods: From a longitudinal cohort, we enrolled 1120 patients with type 2 diabetes who underwent repeated carotid artery ultrasonography every 1-2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01064-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293796PMC

Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome.

Cardiovasc Diabetol 2020 Jun 13;19(1):80. Epub 2020 Jun 13.

Department of Cardiology, Tianjin Chest Hospital, 261 Tai'erzhuang Road, Jinnan District, Tianjin, 300222, China.

Background: The triglyceride-glucose index (TyG index) has been regarded as a reliable alternative marker of insulin resistance and an independent predictor of cardiovascular outcomes. Whether the TyG index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome (ACS) remains uncertain. The aim of this study was to investigate the prognostic value of the TyG index in patients with diabetes and ACS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01054-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293784PMC

Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study.

Cardiovasc Diabetol 2020 Jun 13;19(1):82. Epub 2020 Jun 13.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Background: Reactive hyperemia-peripheral arterial tonometry (RH-PAT) is a noninvasive and simple test for evaluating the endothelial function. There has been sparse evidence on the usefulness of the RH-PAT index (RHI) in predicting future cardiovascular diseases among diabetic patients.

Methods: Asymptomatic diabetic patients with albuminuria were selected; their medical history and laboratory findings were evaluated every 3 to 4 months, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01062-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293773PMC

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.

Cardiovasc Diabetol 2020 Jun 13;19(1):85. Epub 2020 Jun 13.

Department of Cardiovascular Medicine, Saga University, Saga, Japan.

Background: Type 2 diabetes (T2D) is associated with renal impairment and vascular endothelial dysfunction. Therefore, this pathological connection is an important therapeutic target. Recent cardiovascular and renal outcome trials demonstrated that sodium glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risks of cardiovascular and renal events and mortality in patients with T2D and various other background risks including chronic kidney disease (CKD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01065-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293776PMC

Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study.

Cardiovasc Diabetol 2020 Jun 13;19(1):77. Epub 2020 Jun 13.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea.

Background: We aimed to investigate the hazard of hospitalization for heart failure (hHF) according to the transitions in metabolic health and obesity status.

Methods: The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this nationwide, longitudinal, population-based study. The hazard of hHF was analyzed according to the eight groups stratified by stability in metabolic health and transition in obesity status among initially metabolically healthy adults who underwent two cycles of health examinations in 2009-2010 and 2013-2014 (N = 7,148,763). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01051-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293788PMC

Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity.

Cardiovasc Diabetol 2020 Jun 13;19(1):79. Epub 2020 Jun 13.

Department of Military Medicine, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.

Severe obesity among children and adolescents is a significant global public health concern. The prevalence has markedly increased over the last decades, becoming common in many countries. Overwhelming rates of obesity among youth have prompted efforts to identify an evidence-based immediate- and long-term cardiometabolic risk factor profile in childhood-onset severe obesity, and to highlight gaps that require further investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01052-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293793PMC

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.

Cardiovasc Diabetol 2020 Jun 13;19(1):83. Epub 2020 Jun 13.

Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.

Background: Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of GLP-1ra in comparisons with dipeptidyl peptidase-4 inhibitor (DPP-4i), sulfonylurea (SU), and insulin in a real-world population with T2D.

Methods: Adults with newly-diagnosed T2D were identified from Taiwan's National Health Insurance Research Database in 2003-2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01053-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293792PMC

High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study.

Cardiovasc Diabetol 2020 Jun 13;19(1):78. Epub 2020 Jun 13.

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK.

Background: Bodyweight variability is a risk factor for atrial fibrillation (AF). We aimed to examine the relationship between bodyweight variability and the risk of AF in patients with type 2 diabetes mellitus (DM), and whether this relationship was affected by baseline body mass index (BMI), weight change, or advanced diabetic stage.

Methods: A nationwide population-based cohort of 670,797 patients with type 2 DM from the Korean National Health Insurance Service database without a history of AF and with ≥ 3 measurements of bodyweight over a 5-year period were followed up for AF development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01059-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293783PMC

Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes.

Cardiovasc Diabetol 2020 Jun 11;19(1):75. Epub 2020 Jun 11.

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.

Background: Although an increased arterial stiffness has been associated with traditional coronary risk factors, the risk factors and pathology of arterial stiffness remain unclear. In this study, we aimed to identify the plasma metabolites associated with arterial stiffness in patients with type 2 diabetes mellitus.

Methods: We used the metabolomic data of 209 patients with type 2 diabetes as the first dataset for screening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01057-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291560PMC

Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19.

Cardiovasc Diabetol 2020 06 11;19(1):76. Epub 2020 Jun 11.

Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.

A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Covid-19 infection. However, the rates of severe disease are significantly higher in patients with diabetes compared with non-diabetes (34. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01047-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289072PMC

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.

Cardiovasc Diabetol 2020 Jun 10;19(1):74. Epub 2020 Jun 10.

Department of Medicine, University of Padova, Via Giustiniani 2, 35100, Padua, Italy.

Background: Cardiovascular outcome trials in high-risk patients showed that some GLP-1 receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent cardiovascular events in type 2 diabetes (T2D). Since no trial has directly compared these two classes of drugs, we performed a comparative outcome analysis using real-world data.

Methods: From a database of ~ 5 million people from North-East Italy, we retrospectively identified initiators of GLP-1RA or DPP-4i from 2011 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01049-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288543PMC

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.

Cardiovasc Diabetol 2020 Jun 5;19(1):73. Epub 2020 Jun 5.

Division of Cardiology, Department of Internal Medicine, Chung Shan Medical University Hospital and Chung Shan Medical University, Taichung, Taiwan, ROC.

Background: Clinical trials have shown the cardiovascular protective effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and the risk of arrhythmias. This study aimed to evaluate the risk of new-onset arrhythmias (NOA) and all-cause mortality with the use of SGLT2 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01048-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275510PMC

Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.

Cardiovasc Diabetol 2020 06 3;19(1):72. Epub 2020 Jun 3.

The GW Medical Faculty Associates, 2300 M Street NW, Washington, DC, 20037, USA.

Background: Endothelial Progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. EPCs have been shown to be a robust cardiovascular disease (CVD) risk indicator. Cellular mechanisms of DPP4 inhibitors such as linagliptin (LG) on CVD risk, in patients with T2DM with established CKD has not been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01046-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271387PMC
June 2020
4.015 Impact Factor

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome.

Cardiovasc Diabetol 2020 May 30;19(1):71. Epub 2020 May 30.

Department of Cardiovascular Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, No. 358 Gaoqiaodatong Road, Pudong District, Shanghai, 200137, China.

Background: Postprandial hyperglycemia was reported to play a key role in established risk factors of coronary artery diseases (CAD) and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of short-term postprandial glucose (PPG) excursions. Low serum 1,5-AG levels have been associated with occurrence of CAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01045-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261377PMC

Metabolic syndrome and myocardium steatosis in subclinical type 2 diabetes mellitus: a H-magnetic resonance spectroscopy study.

Cardiovasc Diabetol 2020 May 29;19(1):70. Epub 2020 May 29.

Department of Radiology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

Background: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that collectively cause an increased risk of type 2 diabetes mellitus (T2DM) and nonatherosclerotic cardiovascular disease. This study aimed to evaluate the role of myocardial steatosis in T2DM patients with or without MetS, as well as the relationship between subclinical left ventricular (LV) myocardial dysfunction and myocardial steatosis.

Methods And Materials: We recruited 53 T2DM patients and 20 healthy controls underwent cardiac magnetic resonance examination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01044-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260782PMC

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.

Cardiovasc Diabetol 2020 May 28;19(1):69. Epub 2020 May 28.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.

Background: The effects of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on cardiac function are not fully understood. We investigated the changes in cardiac function in diabetic patients according to the presence and types of heart failure (HF).

Methods: We retrospectively identified 202 diabetic patients who underwent echocardiography before, and 6 to 24 months after the initiation of SGLT2i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01042-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254690PMC

Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status.

Cardiovasc Diabetol 2020 May 19;19(1):68. Epub 2020 May 19.

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.

Background: ABO blood groups have previously been associated with cardiovascular disease (CVD) in the general population. This study aimed to investigate the potential relationship between ABO blood groups and CVD in individuals with type 1 diabetes according to diabetic nephropathy (DN) status.

Methods: Adults with type 1 diabetes (4531 individuals) from the FinnDiane Study were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01038-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238526PMC

Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study.

Cardiovasc Diabetol 2020 May 16;19(1):67. Epub 2020 May 16.

Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Research, College of Pharmacy, Yonsei University, 162-1 Songdo-dong, Yeonsu-gu, Incheon, South Korea.

Background: We evaluated the effect of statin use on new-onset type 2 diabetes among individuals without atherosclerotic cardiovascular disease (ASCVD) using nationally representative South Korean claims data (2002-2013, N = 1,016,820).

Methods: A total of 13,698 patients (statin users 5273, non-statin users 5273) aged 40-74 years, newly diagnosed with dyslipidemia but without any history of diabetes or ASCVD, were selected in 2005. We followed up the final sample until 2013 and evaluated the cumulative incidence of type 2 diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01037-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231413PMC

Empagliflozin prevents doxorubicin-induced myocardial dysfunction.

Cardiovasc Diabetol 2020 May 15;19(1):66. Epub 2020 May 15.

Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.

Background: Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover, the EMPA-REG OUTCOME trial demonstrated a 14% reduction of major adverse cardiovascular events (MACE), a 38% reduction in cardiovascular (CV) death and a 35% reduction in the hospitalization rate for heart failure (HF). These beneficial effect on HF were apparently independent from glucose control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01040-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229599PMC

Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.

Authors:
Milton Packer

Cardiovasc Diabetol 2020 May 13;19(1):62. Epub 2020 May 13.

Baylor Heart and Vascular Institute, Baylor University Medical Center, 621 N. Hall Street, Dallas, TX, 75226, USA.

Autophagy is a lysosome-dependent intracellular degradative pathway, which mediates the cellular adaptation to nutrient and oxygen depletion as well as to oxidative and endoplasmic reticulum stress. The molecular mechanisms that stimulate autophagy include the activation of energy deprivation sensors, sirtuin-1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK). These enzymes not only promote organellar integrity directly, but they also enhance autophagic flux, which leads to the removal of dysfunctional mitochondria and peroxisomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01041-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222526PMC

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.

Cardiovasc Diabetol 2020 May 13;19(1):63. Epub 2020 May 13.

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.

Background: Evidence of adverse clinical outcomes for non-vitamin K antagonist oral anticoagulant (NOACs) and warfarin in patients with atrial fibrillation (AF) and diabetes mellitus are limited. We investigated the effectiveness, safety, and major adverse limb events for NOACs versus warfarin among diabetic AF patients.

Methods: In this nationwide retrospective cohort study collected from Taiwan National Health Insurance Research Database, we identified a total of 20,967 and 5812 consecutive AF patients with diabetes taking NOACs and warfarin from June 1, 2012, to December 31, 2017, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01043-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222472PMC

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.

Cardiovasc Diabetol 2020 May 13;19(1):65. Epub 2020 May 13.

Endocrinology, Diabetology & Nutrition, CHRU of Nancy, Brabois Hospital, Lorraine University, 54500, Vandoeuvre-lès-Nancy, France.

The recent results of Cardiovascular Outcomes Trials (CVOTs) in type 2 diabetes have clearly established the cardiovascular (CV) safety or even the benefit of two therapeutic classes, Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA) and Sodium-Glucose Co-Transporter-2 inhibitors (SGLT-2i). Publication of the latest CVOTs for these therapeutic classes also led to an update of ESC guidelines and ADA/EASD consensus report in 2019, which considers using GLP-1 RA or SGLT-2i with proven cardiovascular benefit early in the management of type 2 diabetic patient with established cardiovascular disease (CVD) or at high risk of atherosclerotic CVD. The main beneficial results of these time-to event studies are supported by conventional statistical measures attesting the effectiveness of GLP-1 RA or SGLT2i on cardiovascular events (absolute risk, absolute risk difference, relative risk, relative risk reduction, odds ratio, hazard ratio). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01034-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222529PMC

Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy.

Cardiovasc Diabetol 2020 May 13;19(1):64. Epub 2020 May 13.

Department of Cardiovascular Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vascular Diseases, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China.

Background: Type 2 diabetes mellitus is common in cardiovascular disease. It is associated with adverse clinical outcomes for patients who had undergone coronary artery bypass and valve operations. The aim of this study was to evaluate the impact of type 2 diabetes mellitus on the midterm outcomes of patients with hypertrophic cardiomyopathy who underwent septal myectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-020-01036-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222568PMC